LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Unicycive Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR UNICYCIVE THERAPEUTICS, INC. INVESTMENTS, CLICK HERE BEFORE NOVEMBER 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
The complaint filed in this class action alleges that between December 29, 2025 and June 29, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) that, as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. What's The Next Step?
Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. Please contact us to learn more about your rights and interests by clicking here, by email (shareholders@glancylaw.com), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224). You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet. Why Glancy Prongay Wolke & Rotter LLP?
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-therapeutics-inc-uncy-shareholders-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302875177.html
SOURCE Glancy Prongay Wolke & Rotter LLP | 
